"The immunotherapy pembrolizumab (Keytruda, Merck & Co) has been approved for use in the treatment of head and neck cancer by the US Food and Drug Administration (FDA).
This is the third cancer indication for the drug; it "...
Discuss the following with patients prior to treatment with Kyprolis:
Counsel patients to avoid dehydration, since patients receiving Kyprolis therapy may experience vomiting and/or diarrhea. Instruct patients to seek medical advice if they experience symptoms of dehydration [see WARNINGS AND PRECAUTIONS].
Advise patients that they may experience cough or shortness of breath (dyspnea) during treatment with Kyprolis. This most commonly occurs within a day of dosing. Advise patients to contact their physician if they experience shortness of breath [see WARNINGS AND PRECAUTIONS].
Inform patients of the risk of venous thromboembolism and discuss the options for prophylaxis. Advise patients to seek immediate medical attention for symptoms of venous thrombosis or embolism [see WARNINGS AND PRECAUTIONS].
Advise patients of the risk of infusion reactions, and discuss the common signs and symptoms of infusion reactions with the patients [see WARNINGS AND PRECAUTIONS].
Inform patients that they may bruise or bleed more easily or that it may take longer to stop bleeding and to report to their physician any prolonged, unusual or excessive bleeding. Instruct patients on the signs of occult bleeding [see WARNINGS AND PRECAUTIONS].
Advise patients that Kyprolis may cause fatigue, dizziness, fainting, and/or drop in blood pressure. Advise patients not to drive or operate machinery if they experience any of these symptoms [see ADVERSE REACTIONS].
Counsel females of reproductive potential to use effective contraceptive measures to prevent pregnancy during and for at least 30 days after treatment with Kyprolis. Counsel males of reproductive potential to use effective contraceptive measures to prevent pregnancy during and for at least 90 days after treatment with Kyprolis. Advise the patient to contact their physician immediately if pregnancy does occur during these times. Advise patients not to take Kyprolis treatment while pregnant or breastfeeding. If a patient wishes to restart breastfeeding after treatment, advise her to discuss the appropriate timing with her physician [see WARNINGS AND PRECAUTIONS and Use In Specific Populations].
Advise patients to discuss with their physician any medication they are currently taking prior to starting treatment with Kyprolis, or prior to starting any new medication(s) during treatment with Kyprolis.
Last reviewed on RxList: 12/12/2016
This monograph has been modified to include the generic and brand name in many instances.
Additional Kyprolis Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.